Remove 2030 Remove Conditions Remove Patients Remove Programs
article thumbnail

Americans Will Cultivate Over 4 Billion Grams Of Homegrown Cannabis in 2022

Veriheal

Despite the federal illegality of cannabis, lawmakers and state representatives have implemented successful medical and recreational cannabis programs across the nation. With legalization, patients and consumers have more freedom in product choice, and many are turning to homegrown cannabis. Cultivation Costs for Homegrowers.

article thumbnail

Medxtractor Doubles Down on B2B Licensing & mHealth

Cannabis Law Report

Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. The company anticipates launching both programs this year. Mental health disorders are notoriously difficult to diagnose and treat. Medxtractor Corp. compound annual growth rate from $2.8 billion in 2020 to $7.6

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

MedXtractor Fills a Key Gap in Mental Health Treatments

Cannabis Law Report

According to the Lancet Commission, mental health disorders are on the rise in every country worldwide, and the resulting lost productivity will cost the global economy $16 trillion by 2030. Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated.

article thumbnail

Is weed legal in Switzerland?

The Cannigma

In a June, 2020 interview, a Swiss drug policy expert told Marijuana Business Daily that the scientific process behind the pilot program is expected to last five years, and that if everything goes as planned, the matter of full recreational cannabis legalization for adults could be debated by 2030. Is CBD legal in Switzerland?

article thumbnail

Further Consideration of the STATES Act

Cannabis Law Report

Permits the distribution of medicinal marihuana only to hospitals and pharmacies registered to dispense Schedule II controlled substances for the purposes of treating glaucoma or the nausea of cancer patients or research approved under the Federal Food, Drug, and Cosmetic Act.”. [ii] 2030 , 2068, 2070; Pub. 10, 1978 , 92 Stat.

Banking 45